INBRAIN and MINIGRAPH Consortium Develop Robotic Implantation for Graphene Brain-Computer Interfaces

INBRAIN Neuroelectronics has announced the successful completion of MINIGRAPH (Minimally Invasive Neuromodulation Implant and implantation procedure based on ground-breaking GRAPHene technology for treating brain disorders), a European Innovation Council-funded project focused on minimally invasive neuromodulation implants and implantation procedures based on graphene technology for treating brain disorders. The consortium developed ultra-thin graphene neural interfaces, implantable electronics, and autonomous software, together with a minimally invasive robotic implantation procedure designed to enable more precise and potentially more scalable deployment of next-generation brain-computer interfaces (BCI).
Using Parkinson’s disease as its initial application, MINIGRAPH took an integrated approach to developing autonomous therapeutics. Deep brain stimulation is already used to treat Parkinson’s disease, but next-generation autonomous therapies will require chronic, implantable medical-grade systems capable of precisely recording neural activity, interpreting those signals, and delivering targeted neuromodulation in response. With INBRAIN leading clinical translation, the consortium was coordinated by the Catalan Institute of Nanoscience and Nanotechnology and also included imec, Fraunhofer-Gesellschaft, Leiden University Medical Center, ETH Zurich, Nanoflex Robotics, and Palacký University Olomouc.
A major focus of MINIGRAPH was the development and evaluation of graphene-based neural interfaces designed to address limitations with existing electrode materials. At the core of the project was INBRAIN’s graphene-based thin-film neural electrode technology, which formed the foundation for both cortical and subcortical neural probes. The consortium generated data supporting more than 10 years of projected stability through accelerated ageing tests, alongside functional performance demonstrated in laboratory and preclinical studies, and conducted extensive toxicity and biocompatibility studies at the cellular and molecular levels.
Nanoflex Robotics and ETH Zurich developed the robotic implantation system for the graphene neural electrodes based on remote magnetic navigation. The consortium adapted a magnetic carrier to deploy the ultra-thin probes and a robotic system designed to precisely guide cortical and subcortical implants along both straight and curved trajectories under X-ray imaging, giving surgeons more options and precision during device implantation. The procedure was validated both in vitro and in vivo in a large animal model, establishing a potential pathway toward faster, more reproducible implantation while preserving electrode functionality.
MINIGRAPH brought together the individual technologies required for an autonomous neuroelectronic therapeutic system, including epicortical and subcortical graphene neural probes, advanced implantable electronics, an integrated functional prototype, the robotic implantation procedure, and autonomous software for brain neuromodulation. The integrated implantable prototype was functionally validated in a translational model, and the consortium advanced compact implantable electronics capable of decoding signals from hundreds of neural sites while enabling precision neuromodulation. The longer-term objective is to enable neuroelectronic systems that continuously record neural activity, interpret disease-relevant signals, and deliver precise, targeted neuromodulation in response.
Jose A. Garrido, Ph.D., Co-Founder and Chief Scientific Officer of INBRAIN, said that as BCI technologies move toward patients, making them available to more people will depend not only on the ability to manufacture advanced devices but also on developing precise and reproducible ways to implant them. Garrido noted that MINIGRAPH brought together the neural interface, intelligent electronics, autonomous software, and robotics as a single integrated system, and that this work helps build the foundation for autonomous neurotherapeutics that can decode neural activity and deliver precise neuromodulation accessible to more patients at scale.
Matt Curran, Co-Founder and CEO of Nanoflex Robotics, said the MINIGRAPH project demonstrated the feasibility and potential to use electromagnetic robotics to control the delivery of next-generation BCIs not only through straight but also curved trajectories deep into the brain with submillimeter accuracy. Curran noted that this will give surgeons more options for how they can implant these devices in the future. Separately from MINIGRAPH, INBRAIN also has a collaboration with Robeauté to explore how microrobotic neurosurgical technologies could make neural implantation more precise, scalable, and accessible, though Robeauté is not affiliated with the MINIGRAPH consortium.
